AR004093A1 - THE USE OF A PROTEIN DERIVED FROM A MAMMALIAN CHEMIOQUINE AND A USEFUL MEDICINAL PRODUCT TO MOBILIZE HEMATOPOIETIC STEM CELLS. - Google Patents

THE USE OF A PROTEIN DERIVED FROM A MAMMALIAN CHEMIOQUINE AND A USEFUL MEDICINAL PRODUCT TO MOBILIZE HEMATOPOIETIC STEM CELLS.

Info

Publication number
AR004093A1
AR004093A1 ARP960104890A ARP960104890A AR004093A1 AR 004093 A1 AR004093 A1 AR 004093A1 AR P960104890 A ARP960104890 A AR P960104890A AR P960104890 A ARP960104890 A AR P960104890A AR 004093 A1 AR004093 A1 AR 004093A1
Authority
AR
Argentina
Prior art keywords
stem cells
mammalian
protein derived
chemioquine
hematopoietic stem
Prior art date
Application number
ARP960104890A
Other languages
Spanish (es)
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of AR004093A1 publication Critical patent/AR004093A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/49—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se presenta el uso de una proteína derivada de una quimioquina de mamífero y el medicamento útil para movilizar células troncohematopoyéticas procedentes de la médula ósea hacia la circulación periférica mediante administración a unanima l de una cantidad eficaz de las formasmaduras, modificadas o multiméricas de KC, gro-beta, gro-alfa, ó gro-gamma.The use of a protein derived from a mammalian chemokine and the drug useful for mobilizing stem cells from the bone marrow into the peripheral circulation by administering to an animal an effective amount of the mature, modified or multimeric forms of KC, gro -beta, gro-alpha, or gro-gamma.

ARP960104890A 1995-10-24 1996-10-24 THE USE OF A PROTEIN DERIVED FROM A MAMMALIAN CHEMIOQUINE AND A USEFUL MEDICINAL PRODUCT TO MOBILIZE HEMATOPOIETIC STEM CELLS. AR004093A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US54726295A 1995-10-24 1995-10-24

Publications (1)

Publication Number Publication Date
AR004093A1 true AR004093A1 (en) 1998-09-30

Family

ID=24183989

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960104890A AR004093A1 (en) 1995-10-24 1996-10-24 THE USE OF A PROTEIN DERIVED FROM A MAMMALIAN CHEMIOQUINE AND A USEFUL MEDICINAL PRODUCT TO MOBILIZE HEMATOPOIETIC STEM CELLS.

Country Status (14)

Country Link
EP (1) EP0866806A4 (en)
JP (1) JPH11512747A (en)
KR (1) KR19990066997A (en)
AR (1) AR004093A1 (en)
AU (1) AU712235B2 (en)
BR (1) BR9611173A (en)
CZ (1) CZ120298A3 (en)
HU (1) HUP9802531A3 (en)
NO (1) NO981818L (en)
NZ (1) NZ321789A (en)
PL (1) PL326364A1 (en)
TR (1) TR199800742T2 (en)
WO (1) WO1997015595A1 (en)
ZA (1) ZA968896B (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391589B1 (en) 1994-08-23 2002-05-21 Human Genome Sciences, Inc. Human chemokine beta-10 mutant polypeptides
US6174995B1 (en) 1994-08-23 2001-01-16 Haodong Li Human chemokines, CKβ4 and CKβ10/MCP-4
US6458349B1 (en) 1995-06-02 2002-10-01 Human Genome Sciences, Inc. Chemokine β-4 polypeptides
US6042821A (en) * 1995-11-21 2000-03-28 Smithkline Beecham Corporation Method of treating sepsis with chemokines
US6290948B1 (en) 1996-05-14 2001-09-18 Smithkline Beecham Corporation Method of treating sepsis and ARDS using chamohine beta-10
PL340754A1 (en) * 1997-11-26 2001-02-26 Smithkline Beecham Corp Method activating haemoblast-type stem cells
WO2000074629A2 (en) * 1999-06-08 2000-12-14 Transgene S.A. Composition for implementing a cytotoxic, in particular an antitumoral or antiviral, treatment in a mammal
EP1303292A4 (en) * 2000-06-30 2007-08-22 Smithkline Beecham Corp Chemokine conjugates
JP3563366B2 (en) 2001-05-07 2004-09-08 独立行政法人 科学技術振興機構 Protein multimers with unfolding activity on protein conformation
IL146970A0 (en) * 2001-12-06 2002-08-14 Yeda Res & Dev Migration of haematopoietic stem cells and progenitor cells to the liver
WO2003092597A2 (en) 2002-05-01 2003-11-13 Human Genome Sciences, Inc. Antibodies that specifically bind to chemokine beta-4
SG10201509499RA (en) 2010-11-19 2015-12-30 Eisai R&D Man Co Ltd Neutralizing anti-ccl20 antibodies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0713495B1 (en) * 1993-06-08 2003-11-05 Smithkline Beecham Corporation Methods of enhancing bioactivity of chemokines
GB9426012D0 (en) * 1994-12-22 1995-02-22 British Biotech Pharm Mobilisation of haematopoietic cells
GB9517014D0 (en) * 1995-08-19 1995-10-25 British Biotech Pharm Haematopoietic recovery

Also Published As

Publication number Publication date
BR9611173A (en) 1999-03-30
AU712235B2 (en) 1999-11-04
JPH11512747A (en) 1999-11-02
EP0866806A4 (en) 2002-01-09
MX9803217A (en) 1998-09-30
NZ321789A (en) 2000-07-28
TR199800742T2 (en) 1998-08-21
WO1997015595A1 (en) 1997-05-01
NO981818D0 (en) 1998-04-23
PL326364A1 (en) 1998-09-14
AU7520996A (en) 1997-05-15
NO981818L (en) 1998-06-17
EP0866806A1 (en) 1998-09-30
CZ120298A3 (en) 1998-09-16
HUP9802531A3 (en) 2001-08-28
ZA968896B (en) 1997-04-24
HUP9802531A2 (en) 1999-02-01
KR19990066997A (en) 1999-08-16

Similar Documents

Publication Publication Date Title
ES2163034T3 (en) MICELLARY COMPOSITIONS OF POLYETER BLOCK COPOLYMERS, FOR THE OBJECTIVATION OF BIOLOGICAL AGENTS AS DIANA.
ES2074042T3 (en) RECOMBINANT EXOTOXIN OF PSEUDOMONAS CONSTRUCTION OF AN ACTIVE IMMUNOTOXIN WITH MINOR SIDE EFFECTS.
ES2102196T3 (en) PERIPHERIALIZATION OF HEMATOPOYETIC PLURIPOTENTIAL CELLS.
ATE242633T1 (en) DIALKYLFUMARATE FOR THE TREATMENT OF AUTOIMMUNE DISEASES
FR2442054A1 (en) PURIFIED PROTEINS, IN PARTICULAR INTERFERON, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
EA200000298A1 (en) Prostaglandin agonists and their application for the treatment of bone diseases
PT801649E (en) USEFUL HYDROXYLAMINE DERIVATIVES TO INCREASE THE PRODUCTION OF ADVENTIABLE MOLECULAR PROTEINS AND THEIR PREPARATION
HRP20020787B1 (en) Method of treatment using ligand-immunogen conjugates
AR004093A1 (en) THE USE OF A PROTEIN DERIVED FROM A MAMMALIAN CHEMIOQUINE AND A USEFUL MEDICINAL PRODUCT TO MOBILIZE HEMATOPOIETIC STEM CELLS.
AR003427A1 (en) PEPTIDES RELATED TO DOLASTATIN, PROCEDURE FOR PREPARING THEM, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THE USE OF THE SAME FOR THE PREPARATION OF SUCH PHARMACEUTICAL COMPOSITIONS.
MX9306220A (en) PTP 1D: A NOVYOSE THYROSINE PHOSPHATASE PROTEIN.
ES2231826T3 (en) ANTI-CD6 MONOCLONAL ANTIBODIES FOR THE TREATMENT AND DIAGNOSIS OF PSORIASIS.
ES2196082T3 (en) ANALAGOS OF THE QUERATINOCIT GROWTH FACTOR.
FR2707882B1 (en) New protein anti-mediator therapeutic kits, preparation process and pharmaceutical compositions containing them.
FI972308A0 (en) 2-Substituted 1,2,5-thiadiazolidin-3-one 1,1-dioxides and compositions containing them and methods for their use
ES2151607T3 (en) GROWTH AND DIFFERENTIATION FACTOR 12.
Arnett Osteoclast biology
DK0614456T3 (en) 1alpha, 24 (S) -dihydroxy vitamin D2, its preparation and use
AU9363398A (en) Hepatitis c receptor protein cd81
BG105275A (en) Tan-1057 derivatives
EA199700241A1 (en) NEW, DETERMINED BY COMPOSITION OF A MIXTURE OF ENZYMES FOR ISOLATION OF CELLS AND TREATMENT OF THE RAS
MX9101958A (en) AMINOSULFONYL UREA ACAT INHIBITORS
ZA894013B (en) Combination of angiotensin converting enzyme inhibitors with potassium channel modulators and use thereof in pharmaceuticals
TR199900596T2 (en) Use of proteins as agents against autoimmune diseases.
ES2044170T3 (en) STRONTIUM SALT, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS THAT CONTAIN IT.